Teva’s AJOVY shows promising results in migraine prevention Phase IV study

New interim analysis from the pan-European PEARL Phase IV study reveals that Teva Pharmaceutical Industries' AJOVY (fremanezumab) has led to a significant reduction in monthly ... Read More